VPN Plus+ ExclusiveLess Fear, More Hope: How Research is Driving New Strategies in Hemangiosarcoma Treatment and PreventionDecember 11, 2025In this session: Antonella Borgatti, DVM, MS, DACVIM (Oncology), DECVIM-CA, enlightens attendees with original research from the University of Minnesota on eBAT, a first-in-class bispecific targeted angiotoxin. eBAT is designed to selectively eliminate tumor cells and tumor-initiating cells, offering dual potential as both a therapeutic and preventive option in high-risk canine populations.
SPONSORED CONTENTSwitch to Triple Protection in One Monthly DoseSee the difference of triple protection with the one monthly chew. + Learn More
